SREBF1 and metabolic dysfunction-associated steatotic liver disease: In the liver, it is well established that the activation of both SREBP1 and mTORC1 transcriptions regulates de novo lipogenesis and biosynthesis of FFAs and TG, contributing to NAFLD pathogenesis (40).